Literature DB >> 27686452

MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.

Dezhi Cheng1, Yi Xu2, Changzheng Sun2, Zhifeng He3.   

Abstract

As one of the most widely used chemotherapy drugs for lung cancer, chemoresistance of cisplatin (DPP) is one of the major hindrances in treatment of this malignancy. The microRNAs (miRNAs) have been identified to mediate chemotherapy drug resistance. MiR-451 as a tumor suppressor has been evaluated its potential effect on the sensitivity of cancer cells to DDP. However, the role of miR-451 in regulatory mechanism of chemosensitivity in lung cancer cells is still largely unknown. In this study, we first constructed a cisplatin-resistant A549 cell line (A549/DPP) accompanied with a decreased expression of miR-451 and an increased expression of Mcl-1in the drug resistant cells compared with the parental cells. Exogenous expression of miR-451 level in A549/DPP was found to sensitize their reaction to the treatment of cisplatin, which coincides with reduced expression of Mcl-1. Interestingly, Mcl-1 knockdown in A549/DPP cells increased the chemosensitivity to DPP, suggesting the dependence of Mcl-1 regulation in miR-451 activity. Moreover, miR-451 can restore cisplatin treatment response in cisplatin-resistant xenografts in vivo, while Mcl-1 protein levels were decreased. Thus, these findings provided that in lung cancer cells, tumor suppressor miR-451 enhanced DPP sensitivity via regulation of Mcl-1 expression, which could be served as a novel therapeutic target for the treatment of chemotherapy resistant in lung cancer.

Entities:  

Keywords:  Chemoresistance; Cisplatin; Lung cancer; Mcl-1; MiR-451

Mesh:

Substances:

Year:  2016        PMID: 27686452     DOI: 10.1007/s11010-016-2827-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

1.  Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer.

Authors:  Masayoshi Toge; Satoru Yokoyama; Shinichiro Kato; Hiroaki Sakurai; Kazutaka Senda; Yoshinori Doki; Yoshihiro Hayakawa; Naoki Yoshimura; Ikuo Saiki
Journal:  Int J Oncol       Date:  2015-01-30       Impact factor: 5.650

2.  MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

Authors:  Nerea Bitarte; Eva Bandres; Valentina Boni; Ruth Zarate; Javier Rodriguez; Marisol Gonzalez-Huarriz; Ines Lopez; Jesus Javier Sola; Marta M Alonso; Puri Fortes; Jesus Garcia-Foncillas
Journal:  Stem Cells       Date:  2011-11       Impact factor: 6.277

3.  MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.

Authors:  Dongqin Chen; Jiayuan Huang; Kai Zhang; Banzhou Pan; Jing Chen; Wei De; Rui Wang; Longbang Chen
Journal:  Eur J Cancer       Date:  2014-10-10       Impact factor: 9.162

Review 4.  New and emerging developments in extensive-stage small cell lung cancer therapeutics.

Authors:  Mamta Parikh; Jonathan Riess; Primo N Lara
Journal:  Curr Opin Oncol       Date:  2016-03       Impact factor: 3.645

5.  Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival.

Authors:  Lana Bijelic; Anjali S Kumar; O Anthony Stuart; Paul H Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-26       Impact factor: 2.260

6.  Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).

Authors:  Hai-Bo Bian; Xuan Pan; Jin-Song Yang; Zhao-Xia Wang; Wei De
Journal:  J Exp Clin Cancer Res       Date:  2011-02-17

7.  Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer.

Authors:  E P Booy; E S Henson; S B Gibson
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

8.  Anthocyanins From the Fruit of Vitis coignetiae Pulliat Potentiate the Cisplatin Activity by Inhibiting PI3K/Akt Signaling Pathways in Human Gastric Cancer Cells.

Authors:  Jing Nan Lu; Won Sup Lee; Arulkumar Nagappan; Seong-Hwan Chang; Yung Hyun Choi; Hye Jung Kim; Gon Sup Kim; Chung Ho Ryu; Sung Chul Shin; Jin-Myung Jung; Soon Chan Hong
Journal:  J Cancer Prev       Date:  2015-03

9.  The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Authors:  Chander Peddaboina; Daniel Jupiter; Steven Fletcher; Jeremy L Yap; Arun Rai; Richard P Tobin; Weihua Jiang; Philip Rascoe; M Karen Newell Rogers; W Roy Smythe; Xiaobo Cao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

10.  MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.

Authors:  Masayuki Hiraki; Yozo Suzuki; Maroof Alam; Kunihiko Hinohara; Masanori Hasegawa; Caining Jin; Surender Kharbanda; Donald Kufe
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

View more
  15 in total

Review 1.  Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Authors:  Alti Dayakar; Kumar D Shanmukha; Suresh K Kalangi
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.742

2.  Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.

Authors:  Jiyun Cui; Jing Wang; Yuyao Shen; Dianjie Lin
Journal:  Genes Genomics       Date:  2021-01-18       Impact factor: 1.839

3.  Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1.

Authors:  Jie Zhu; Zhenjie Li
Journal:  Oncotarget       Date:  2017-09-23

4.  Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.

Authors:  Wujian Zheng; Qi Feng; Jiao Liu; Yanke Guo; Lvfen Gao; Ruiman Li; Meng Xu; Guizhen Yan; Zhinan Yin; Shuai Zhang; Shuangping Liu; Changliang Shan
Journal:  Front Pharmacol       Date:  2017-06-30       Impact factor: 5.810

5.  Highly expressed placental miRNAs control key biological processes in human cancer cell lines.

Authors:  Daniel Onofre Vidal; Anelisa Ramão; Daniel Guariz Pinheiro; Bruna Rodrigues Muys; Julio Cesar Cetrulo Lorenzi; Cleidson de Pádua Alves; Dalila Luciola Zanette; Greice Andreotti de Molfetta; Geraldo Duarte; Wilson Araújo Silva
Journal:  Oncotarget       Date:  2018-05-04

6.  miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.

Authors:  Wei Xu; Zhikun Li; Xiaodong Zhu; Ruijun Xu; Youjia Xu
Journal:  Med Sci Monit       Date:  2018-12-06

7.  Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.

Authors:  Yunxiuxiu Xu; Yu Lai; Linhui Cao; Yanshan Li; Guangcheng Chen; Liang Chen; Hanqin Weng; Tao Chen; Lingyun Wang; Yibiao Ye
Journal:  RNA Biol       Date:  2020-12-31       Impact factor: 4.652

8.  Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells.

Authors:  Feng Liu; Zhouyan Bu; Feng Zhao; Daping Xiao
Journal:  Cancer Sci       Date:  2017-11-10       Impact factor: 6.716

Review 9.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

10.  Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.

Authors:  Qi Shen; Jun Li; Junhua Mai; Zhe Zhang; Andrew Fisher; Xiaoyan Wu; Zhaoqi Li; Maricela R Ramirez; Shuqing Chen; Haifa Shen
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.